Literature DB >> 15549225

[(1)H magnetic resonance spectroscopy (MRS) of the liver and hepatic malignant tumors at 3.0 Tesla].

F Fischbach1, M Thormann, J Ricke.   

Abstract

Use of whole-body MRI beyond 1.5 Tesla (T) has initiated a renaissance in spectroscopic procedures (MRS). The superior signal-to-noise ratio of clinical 3T tomographs allows reliable acquisition of MR spectra not only in fixed organs but also in targets moved by breathing such as the liver. The following contribution describes the principles of (1)H MRS and our own initial experiences with spectroscopy of the liver and hepatic malignant tumors with 3T whole-body MRI.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15549225     DOI： 10.1007/s00117-004-1136-3

Source DB:  PubMed          Journal:  Radiologe        ISSN： 0033-832X            Impact factor:   0.635


  31 in total

1.  Echo-train STIR MRI of the liver: comparison of breath-hold and non-breath-hold imaging strategies.

Authors:  J P Earls; N M Rofsky; D R DeCorato; G A Krinsky; J C Weinreb
Journal:  J Magn Reson Imaging       Date:  1999-01       Impact factor: 4.813

Review 2.  Liver cell hydration.

Authors:  D Häussinger; F Schliess; U Warskulat; S vom Dahl
Journal:  Cell Biol Toxicol       Date:  1997-07       Impact factor: 6.691

3.  Comparison of respiratory suppression methods and navigator locations for MR coronary angiography.

Authors:  M V McConnell; V C Khasgiwala; B J Savord; M H Chen; M L Chuang; R R Edelman; W J Manning
Journal:  AJR Am J Roentgenol       Date:  1997-05       Impact factor: 3.959

4.  Chronic hepatitis: in vivo proton MR spectroscopic evaluation of the liver and correlation with histopathologic findings.

Authors:  S G Cho; M Y Kim; H J Kim; Y S Kim; W Choi; S H Shin; K C Hong; Y B Kim; J H Lee; C H Suh
Journal:  Radiology       Date:  2001-12       Impact factor: 11.105

5.  The contribution of proton magnetic resonance spectroscopy (1HMRS) to clinical brain tumour diagnosis.

Authors:  M Murphy; A Loosemore; A G Clifton; F A Howe; A R Tate; S A Cudlip; P R Wilkins; J R Griffiths; B A Bell
Journal:  Br J Neurosurg       Date:  2002-08       Impact factor: 1.596

6.  Motion correction and lipid suppression for 1H magnetic resonance spectroscopy.

Authors:  J M Star-Lack; E Adalsteinsson; G E Gold; D M Ikeda; D M Spielman
Journal:  Magn Reson Med       Date:  2000-03       Impact factor: 4.668

7.  In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner.

Authors:  Yu-Ting Kuo; Chun-Wei Li; Chao-Yun Chen; Jochi Jao; Ding-Kwo Wu; Gin-Chang Liu
Journal:  J Magn Reson Imaging       Date:  2004-05       Impact factor: 4.813

Review 8.  NMR studies of phospholipid metabolism in hepatic lymphoma.

Authors:  R M Dixon
Journal:  NMR Biomed       Date:  1998-11       Impact factor: 4.044

9.  In vivo H-1 spectroscopy in humans at 1.5 T.

Authors:  M Bárány; B G Langer; R P Glick; P N Venkatasubramanian; A C Wilbur; D G Spigos
Journal:  Radiology       Date:  1988-06       Impact factor: 11.105

10.  Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites.

Authors:  J Frahm; H Bruhn; M L Gyngell; K D Merboldt; W Hänicke; R Sauter
Journal:  Magn Reson Med       Date:  1989-07       Impact factor: 4.668
View more
  2 in total

Review 1.  [New developments in MRI of the liver].

Authors:  N Bastati-Huber; H Prosch; S Baroud; S Magnaldi; W Schima; A Ba-Ssalamah
Journal:  Radiologe       Date:  2011-08       Impact factor: 0.635

2.  MRI of the pelvis at 3 T: very high spatial resolution with sensitivity encoding and flip-angle sweep technique in clinically acceptable scan time.

Authors:  Nuschin Morakkabati-Spitz; Jürgen Gieseke; Christiane Kuhl; Götz Lutterbey; Marcus von Falkenhausen; Frank Träber; Tjoung-Won Park-Simon; Oliver Zivanovic; Hans H Schild
Journal:  Eur Radiol       Date:  2005-10-14       Impact factor: 5.315
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.